Showing results (1-10 of 313) with videos related to
Sort By:
Pageof 32
Open Forum Infectious Diseases|June 24, 2026
What's Behind DOOR Number 2? Recent Applications From Post-Hoc Analyses of Infectious Diseases Randomized Clinical TrialsJason M Pogue, Ryan K ShieldsClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2024
The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?Samuel L Aitken, Virginia M Pierce, Jason M Pogue, et al.Antimicrobial Agents and Chemotherapy|January 28, 2025
Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?Ava J Dorazio, Ellen G Kline, Kevin M Squires, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosaAva J Dorazio, Samuel L Aitken, Virginia M Pierce, et al.Antimicrobial Agents and Chemotherapy|April 6, 2026
Ceftazidime-avibactam resistance evolution in <i>Pseudomonas aeruginosa</i> and implications for cross-resistance to other novel β-lactamsAva J Dorazio, Ellen G Kline, Kevin M Squires, et al.Antimicrobial Agents and Chemotherapy|February 5, 2020
Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?Ryan K ShieldsAntimicrobial Agents and Chemotherapy|June 13, 2023
Case Commentary: When Voldemort Meets Sauron: Treatment Considerations for Emerging Dual-Carbapenemase-Producing Extensively Drug-Resistant Pseudomonas aeruginosaWalaiporn Wangchinda, Jason M PogueThe Annals of Pharmacotherapy|September 6, 2012
Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trialCesar Alaniz, Jason M PoguePharmacotherapy|October 27, 2015
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and ManagementKeith S Kaye, Jason M PogueOpen Forum Infectious Diseases|January 19, 2024
Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury?Jason M Pogue, Samuel L AitkenPageof 32